首页> 美国卫生研究院文献>Neuro-Oncology >P16.13 Surgical Results of Growth Hormone-Secreting Pituitary Adenoma
【2h】

P16.13 Surgical Results of Growth Hormone-Secreting Pituitary Adenoma

机译:P16.13生长激素分泌型垂体腺瘤的手术结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective: We retrospectively analyzed the surgical outcomes of 42 patients with growth hormone (GH)-secreting pituitary adenoma to evaluate the clinical manifestations and to determine which preoperative factors significantly influence remission. >Methods: Forty-two patients with GH-secreting pituitary adenoma underwent transsphenoidal surgery (TSS) between 1995 and 2007. The patient group included 23 women and 19 men, with a mean age of 40.2 (range 13-61) years, and a mean follow-up duration of 49.4 (range 3-178) months after the operation. For comparable radiological criteria, we classified parasellar growth into five grades according to the Knosp classification. We analyzed the surgical results of the patients according to the most recent stringent criteria for cure. >Results: The overall rate of endocrinological remission in the group of 42 patients undergoing primary TSS was 64% (26 of 42). The remission rate was 67% (8 of 12) for microadenoma and 60% (18 of 30) for macroadenoma. The remission rate was 30% (3 of 10) for the group with cavernous sinus invasion and 72% (23 of 32) for the group with intact cavernous sinus. Cavernous sinus invasion in Knosp grade III and IV was significantly correlated with the remission rate. There was a significant relationship between preoperative mean GH concentration and early postoperative outcome, with most patients in remission having a lower preoperative GH concentration. >Conclusion: TSS is thought to be an effective primary treatment for GH-secreting pituitary adenomas according to the most recent criteria of cure. Because the remission rate in cases with cavernous sinus invasion is very low, early detection of the tumor before it extends into the cavernous sinus and a long-term endocrinological and radiological follow-up are necessary in order to improve the remission rate of acromegaly.
机译:>目的:我们回顾性分析了42例分泌生长激素(GH)的垂体腺瘤患者的手术结局,以评估其临床表现并确定哪些术前因素显着影响缓解。 >方法: 1995年至2007年间,有42例分泌GH的垂体腺瘤患者接受了经蝶窦手术(TSS)。患者组包括23名女性和19名男性,平均年龄为40.2岁(范围13-手术后61个月,平均随访时间为49.4个月(范围3-178)。对于可比较的放射学标准,我们根据纳氏(Knosp)分类将鞍旁生长分为五个等级。我们根据最新的严格治疗标准对患者的手术结果进行了分析。 >结果: 42例接受原发性TSS的患者的总内分泌缓解率为64%(42例中的26例)。微腺瘤的缓解率为67%(12分之8),大腺瘤的缓解率为60%(30分之18)。海绵窦浸润组的缓解率是30%(10分之3),而海绵窦完整的组的缓解率是72%(32分之23)。 Knosp III和IV级海绵窦浸润与缓解率显着相关。术前平均GH浓度与术后早期结局之间存在显着的关系,大多数缓解期患者术前GH浓度较低。 >结论:根据最新的治愈标准,TSS被认为是分泌GH的垂体腺瘤的有效主要治疗方法。由于海绵窦浸润的缓解率很低,因此在肿瘤扩散到海绵窦之前要及早发现,并需要长期的内分泌和放射学随访以提高肢端肥大症的缓解率。

著录项

  • 期刊名称 Neuro-Oncology
  • 作者

    O. Kim;

  • 作者单位
  • 年(卷),期 2017(19),Suppl 3
  • 年度 2017
  • 页码 iii112
  • 总页数 1
  • 原文格式 PDF
  • 正文语种
  • 中图分类 神经病学;肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号